Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TransCon PEG treprostinil in healthy volunteers
NCT02149095Phase 1Withdrawn
- Sponsor
- United Therapeutics Corporation
- Start
- Jul 2014
- Primary completion
- Nov 2014
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of treprostinil in pulmonary arterial hypertension (PAH), sponsored by United Therapeutics Corporation. Primary endpoints: Incidence of treatment-emergent Adverse Events at Day 43, Maximum Tolerated Dose at 5 days and 2 more. Planned start Jul 2014; status: withdrawn.
02
Drugs
treprostinil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT02149095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02149095.